Triple Hormone Receptor Agonist Retatrutide for the Treatment of Obesity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
N. Engl. J. Med 2023 Jun 26;[EPub Ahead of Print], AM Jastreboff, LM Kaplan, JP Frías, Q Wu, Y Du, S Gurbuz, T Coskun, A Haupt, Z Milicevic, ML HartmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.